Arrowhead is headed to double the Tirzepatide’s weightloss in the combinational study. After proving its excellence in therapies to cure the diseases causing genes, the company has now entered the obesity area with the weight of responsibility to bring best in class solution to the obesity world. Arrowhead found potential in Eli Lilly’s tirzepatide, which, in no time, cut the fat that triggers metabolic disease.
Arrowhead’s suggestion to double this drug brought 17% of the share profit, as the result was quite convincing. Following this, Arrowhead entered the obesity market with confidence.
The provisional results are fetched from the compact set of patients involved in two Phase 1/2a trials, along with Arrowhead’s ARO-ALK7 and ARO-INHBE RNAi therapeutics. After this trial, the former alleviated the weight by 9.45% at week 16 in a total of four patients having type 2 diabetes in comparison to tirzepatide alone. Arrowhead claimed that this result is more powerful than tirzepatide alone.
The difference shows that around 4.8% weight loss was witnessed at week 16 in five patients who took Lilly’s drug. Whereas, ARO-INHBE massively mitigated liver fat, total fat and visceral fat, giving tough competition to champions as well. Without any supervision by tirzepatide, ARO-INHBE alone cut 38% of liver fat, doubled the lean tissue by 3.6% and cut visceral fat by 9.9%.
Following this, the company not only made a business profit but also gave a blockbuster hit with its debut in the obesity market. Trust Securities also appreciated Arrowhead’s weight loss approach and robust results by calling it ‘meaningful’ and ‘substantial’. The opportunities for Arrowhead are blossoming as the firm is expecting quality and planning to launch oral options. This is a hint to the company that they can come up with a commendable oral option as well to polish and strengthen their excellent initiatives in the weight loss management sector.
The company also dug into one report of limb abscess, calling it similar to gastrointestinal side effects that were seen in tirzepatide alone and in combo as well. This didn’t show a meaningful acceleration of lipid parameters, glycemic indices or liver enzymes that was unveiled in the lab tests. Further, Arrowhead disclosed its primary data for ARO-ALK7 that highlighted a gene as a solution, which happens to be very rare. The company have high hopes for ARO-ALK7.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
